{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:39Z","timestamp":1761870339318,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Novartis Oncology"},{"name":"Singapore Cancer Syndicate","award":["CS50"],"award-info":[{"award-number":["CS50"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.clml.2011.11.002","type":"journal-article","created":{"date-parts":[[2011,12,30]],"date-time":"2011-12-30T16:07:23Z","timestamp":1325261243000},"page":"118-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lower Dose Dexamethasone\/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma"],"prefix":"10.1016","volume":"12","author":[{"given":"Gerrard","family":"Teoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasant R.","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeo-Kyeoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.11.002_bib1","first-page":"87","article-title":"Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma","volume":"21","author":"Bergsagel","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.clml.2011.11.002_bib2","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2011.11.002_bib3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.11.002_bib4","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.11.002_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.11.002_bib6","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.11.002_bib7","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ejca.2010.03.007","article-title":"Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis","volume":"46","author":"Uaprasert","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2011.11.002_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.21734","article-title":"Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience","volume":"85","author":"Guo","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2011.11.002_bib9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00277-009-0856-x","article-title":"Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study","volume":"89","author":"Kim","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2011.11.002_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12185-008-0218-9","article-title":"Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience","volume":"89","author":"L\u00fc","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2011.11.002_bib11","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ar.21218","article-title":"Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China","volume":"293","author":"Chen","year":"2010","journal-title":"Anat Rec (Hoboken)"},{"key":"10.1016\/j.clml.2011.11.002_bib12","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s12185-009-0314-5","article-title":"Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed\/refractory multiple myeloma","volume":"89","author":"Murakami","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2011.11.002_bib13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.hoc.2007.08.007","article-title":"The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies","volume":"21","author":"Mitsiades","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2011.11.002_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bone.2010.06.029","article-title":"Tumor-host cell interactions in the bone disease of myeloma","volume":"48","author":"Fowler","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.clml.2011.11.002_bib15","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clml.2011.11.002_bib16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.4915.4915","article-title":"Low dose dexamethasone and thalidomide with higher frequency zoledronic acid (dtZ) for multiple myeloma","volume":"104","author":"Teoh","year":"2004","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.clml.2011.11.002_bib17","first-page":"141","article-title":"Low dose dexamethasone and thalidomide with higher frequency zoledronic acid (dtZ) for relapsed\/refractory multiple myeloma","volume":"90","author":"Teoh","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.11.002_bib18","first-page":"846","article-title":"Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma","volume":"87","author":"Boccadoro","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.11.002_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bmt.1704173","article-title":"Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma","volume":"32","author":"Ghobrial","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2011.11.002_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2003-04-1045","article-title":"Treatment of multiple myeloma","volume":"103","author":"Barlogie","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.11.002_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2011.11.002_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1601-0825.2008.01494.x","article-title":"Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws","volume":"15","author":"Treister","year":"2009","journal-title":"Oral Dis"},{"key":"10.1016\/j.clml.2011.11.002_bib23","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.11.002_bib24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00432-010-0907-7","article-title":"Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases","volume":"136","author":"Filleul","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2011.11.002_bib25","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.11.002_bib26","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.11.002_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/aja.1001610102","article-title":"The hematogenous origin of osteoclasts: experimental evidence from osteopetrotic (microphthalmic) mice treated with spleen cells from beige mouse donors","volume":"161","author":"Marks","year":"1981","journal-title":"Am J Anat"},{"key":"10.1016\/j.clml.2011.11.002_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00277-009-0807-6","article-title":"Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide","volume":"89","author":"Koh","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2011.11.002_bib29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A'Hern","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2011.11.002_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1073\/pnas.28.3.88","article-title":"On confidence intervals","volume":"28","author":"Wilson","year":"1942","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2011.11.002_bib31","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.11.002_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/0973-1482.63570","article-title":"Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review","volume":"6","author":"Weide","year":"2010","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.clml.2011.11.002_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0609.2007.00974.x","article-title":"Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation","volume":"80","author":"Tosi","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2011.11.002_bib34","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.11.002_bib35","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2141.2009.07803.x","article-title":"Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma","volume":"146","author":"Jagannath","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.11.002_bib36","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2007.12.3323","article-title":"Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multipl myeloma: efficacy and clinical implications of tumor response kinetics","volume":"25","author":"Rosi\u00f1ol","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.11.002_bib37","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.11.002_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2011.11.002_bib39","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4065\/82.10.1179","article-title":"Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma","volume":"82","author":"Lacy","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2011.11.002_bib40","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Corradinients with newly diagnosed multiple myeloma","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.11.002_bib41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.11.002_bib42","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.11.002_bib43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000313787","article-title":"Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws","volume":"124","author":"Allegra","year":"2010","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2011.11.002_bib44","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/jbmr.23","article-title":"Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats","volume":"25","author":"Hokugo","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clml.2011.11.002_bib45","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1538-7836.2009.03312.x","article-title":"Does an active sun exposure habit lower the risk of venous thrombotic events?","volume":"7","author":"Lindqvist","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clml.2011.11.002_bib46","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajh.21412","article-title":"Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma","volume":"84","author":"Ng","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2011.11.002_bib47","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2174\/156800909789760339","article-title":"Anti-tumour effects of bisphosphonates - what have we learned from in vivo models?","volume":"9","author":"Brown","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.clml.2011.11.002_bib48","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.2174\/138161210793563608","article-title":"Bisphosphonate therapy in the treatment of multiple myeloma","volume":"16","author":"Lawson","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clml.2011.11.002_bib49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.24758","article-title":"The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation","volume":"126","author":"Guenther","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2011.11.002_bib50","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.11.002_bib51","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","article-title":"Importance of achieving a complete response in multiple myeloma, and the impact of novel agents","volume":"28","author":"Chanan-Khan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.11.002_bib52","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0b013e3181c51cd4","article-title":"The importance of complete response in outcomes in myeloma","volume":"15","author":"Nooka","year":"2009","journal-title":"Cancer J"},{"key":"10.1016\/j.clml.2011.11.002_bib53","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.11.002_bib54","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cncr.23546","article-title":"Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma","volume":"113","author":"Barlogie","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.11.002_bib55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2353\/ajpath.2009.080627","article-title":"A physical mechanism for coupling bone resorption and formation in adult human bone","volume":"174","author":"Andersen","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2011.11.002_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bone.2010.06.016","article-title":"Osteoblast function in myeloma","volume":"48","author":"Roodman","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.clml.2011.11.002_bib57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11899-009-0015-4","article-title":"The role of bisphosphonates in multiple myeloma","volume":"4","author":"Levy","year":"2009","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2011.11.002_bib58","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/10428190903503438","article-title":"Osteoblastogenesis and tumor growth in myeloma","volume":"51","author":"Yaccoby","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.11.002_bib59","first-page":"462","article-title":"Bone building with bortezomib","volume":"118","author":"Roodman","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2011.11.002_bib60","doi-asserted-by":"crossref","first-page":"11846","DOI":"10.1074\/jbc.M512624200","article-title":"Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression","volume":"281","author":"Yao","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2011.11.002_bib61","doi-asserted-by":"crossref","first-page":"R152","DOI":"10.1186\/ar2046","article-title":"Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts","volume":"8","author":"Komano","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clml.2011.11.002_bib62","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1359\/jbmr.2000.15.8.1467","article-title":"Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298","volume":"15","author":"Coxon","year":"2000","journal-title":"J Bone Miner Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011005787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011005787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:02Z","timestamp":1761870122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011005787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S2152265011005787"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.11.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower Dose Dexamethasone\/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}